Laxmi Dental Ltd — Q4 FY26 earnings call
Summary generated by AI from the official transcript Laxmi Dental Ltd filed with BSE on 30 May 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Laxmi Dental reported Q4 FY26 revenue of Rs. 74 crore, up 22% year-on-year, with EBITDA margin at 18.3% and PAT margin at 13.6%. Management said the dental lab business recorded its highest ever quarterly revenue driven by both domestic recovery and international growth, while the aligner businesses Bizdent and Vedia showed stable to recovering performance. For the full year, revenue grew 16.2% to Rs. 277.9 crore with EBITDA margin of 15.6% and PAT margin of 10.4%.
1 statement from this call is not shown because its supporting quote could not be reproduced within our quoting limits. Nothing shown here is affected: every statement on this page carries its verified quote.
Numbers mentioned
Revenue: Rs. 74 crores (Q4 FY26)
p. 4
“Revenue for Q4 FY '26 stood at INR 74 crores, representing year-on-year growth of 22%.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
Gross profit margin: 70.5% (Q4 FY26)
p. 4
“Gross profit margin stood at 70.5%, which is a minor improvement sequentially despite a relatively higher sales contribution from scanners, which usually comes at a lower margin.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
EBITDA margin: 18.3% (Q4 FY26)
p. 4
“EBITDA and PAT margins for the quarter were recorded at a healthy level of 18.3% and 13.6% respectively.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
Full year revenue growth: 16.2% (FY26)
p. 4
“we still close FY '26 with a healthy growth of 16.2% year-on- year while recording a good set of margins.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
FY26 EBITDA margin: 15.6% (FY26)
p. 4
“EBITDA margins stood at 15.6% and PAT recorded 10.4% for the year.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
Dental lab business revenue: Rs. 45.9 crore (Q4 FY26)
p. 5
“Our dental lab business recorded its highest ever quarterly revenue of Rs. 45.9 crore with a growth of 27% year-on-year.”
Sameer Merchant, page 5 of the filed PDF · View the filing
International lab business growth: 40.9% YOY (Q4 FY26)
p. 5
“Our international lab business delivered a robust growth of 40.9% YOY.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Domestic business growth: 16.3% YOY (Q4 FY26)
p. 5
“Speaking of domestic business, it delivered a solid growth of 16.3% year-on-year.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Bizdent growth: 10.9% YOY (Q4 FY26)
p. 5
“Bizdent, our clear aligner business in India, witnessed a meaningful recovery from the previous quarter and recorded a healthy growth of 10.9% on YOY basis.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Vedia revenue: Rs. 7.3 crores (Q4 FY26)
p. 5
“Vedia, our aligner raw metal business, remained stable sequentially and reported a revenue of Rs. 7.3 crores.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Kids-e-Dental revenue: Rs. 5.4 crores (Q4 FY26)
p. 5
“Speaking of our pediatric dental business, Kids-e-Dental, the revenue stood for the quarter at Rs. 5.4 crores.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Digital penetration in domestic lab business: around 80% (Q4 FY26)
p. 5
“Now, our digital penetration in the domestic lab business stands at around 80% and we are targeting over 90% digital penetration over the medium-term.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Revenue from operations: Rs. 74 crores (Q4 FY26)
p. 6
“We achieved our highest ever revenue from operations at Rs. 74 crores, reflecting a healthy YOY growth of 21.9% compared to Rs. 60.7 crores last year.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Gross profit: Rs. 52.1 crores (Q4 FY26)
p. 6
“Gross profit for the quarter increased by 9.1% YOY to Rs. 52.1 crores with gross margins coming in at 70.5%.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Employee costs: Rs. 26.8 crores (Q4 FY26)
p. 6
“Employee costs for the quarter stood at Rs. 26.8 crores, remaining stable sequentially and registering a YOY increase of 9.6%.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
EBITDA: Rs. 13.5 crores (Q4 FY26)
p. 6
“The company reported EBITDA of Rs. 13.5 crores for the quarter, up 41.8% YOY, while EBITDA margins expanded to 18.3% compared to 15.7% in the same period last year.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Adjusted EBITDA: Rs. 13.1 crores (Q4 FY26)
p. 6
“Adjusted EBITDA, which includes recorded EBITDA, 60% of Kids-e-Dental PAT, 49% of IDBG AI Dent PAT and ESOP expenses, this stood at Rs. 13.1 crores.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Profit Before Tax and Exceptional Items: Rs. 11.1 crores (Q4 FY26)
p. 6
“For better understanding of our performance, one can look at the Profit Before Tax and Exceptional Items which has almost doubled from Q4 FY '25 and stood at Rs. 11.1 crores.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Finance costs: Rs. 0.3 crores (Q4 FY26)
p. 6
“Finance costs for the quarter stood at Rs. 0.3 crores compared to Rs. 1.3 crores last year.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Profit after tax: Rs. 10.1 crores (Q4 FY26)
p. 6
“We reported a profit after tax of Rs. 10.1 crores for the quarter compared to Rs. 4.3 crores in Q4 FY' 25.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
FY26 revenue from operations: Rs. 277.9 crores (FY26)
p. 6
“Coming to our FY '26 performance, revenue from operations stood at Rs. 277.9 crores, registering a growth of 16.2% over Rs. 239.1 crores in the previous year.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
FY26 EBITDA: Rs. 43.4 crores (FY26)
p. 6
“EBITDA for the period stood at Rs. 43.4 crores while adjusted EBITDA came in at Rs. 51.1 crores.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
FY26 Profit Before Tax and Exceptional Items: Rs. 34.7 crores (FY26)
p. 6
“Profit Before Tax and Exceptional Items stood at Rs. 34.7 crores with 40% YOY growth.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
FY26 profit after tax: Rs. 28.9 crores (FY26)
p. 6
“The company reported a profit after tax of Rs. 28.9 crores with a margin of 10.4%.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
CAPEX: Rs. 18.4 crores (FY26)
p. 6
“We have done a CAPEX of around Rs. 18.4 crores in FY '26.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Cash and bank balance including investments: around Rs. 99 crores (FY26)
p. 6
“Our cash and bank balance including investments stood at around Rs. 99 crores.”
Dharmesh Dattani, page 6 of the filed PDF · View the filing
Scanner sales volume: 211 (quarter), 1009 (year) (Q4 FY26 / FY26)
p. 10
“211, on a yearly basis, 1009.”
Sameer Merchant, page 10 of the filed PDF · View the filing
US export revenue share: 20% (Q4 FY26)
p. 14
“So, currently, the US percentage is 20% of our revenue.”
Sameer Merchant, page 14 of the filed PDF · View the filing
Export revenue share: 33%-34% (Q4 FY26)
p. 11
“Export revenue is about 33%-34%.”
Sameer Merchant, page 11 of the filed PDF · View the filing
Current US tariff on exports: about 10% (Q4 FY26)
p. 4
“Currently, the tariff situation is better and we are paying about 10% tariff on our US exports.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Digital penetration in domestic lab business — over 90% · medium-term
stated as an aspiration by Sameer Merchant
p. 5
“Now, our digital penetration in the domestic lab business stands at around 80% and we are targeting over 90% digital penetration over the medium-term.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Revenue growth trajectory — similar to past two to three years · next two to three years
stated as an aspiration by Sameer Merchant
p. 11
“I would say similar, what we have done in the past, if you see what we have done in the last couple of years, I would say, over the last year, we did, last to last year was 24%. This year was 16%.”
Sameer Merchant, page 11 of the filed PDF · View the filing
EBITDA and gross margins — 18%-20% EBITDA, 75%-80% gross margin · FY27 or FY28
stated conditionally by Sameer Merchant
p. 16
“we again are confident to, I think, do what we have done in the past. But again, calling out anything today based on the current situation is not what we want to do today.”
Sameer Merchant, page 16 of the filed PDF · View the filing
CAPEX for FY27 — FY27
stated conditionally by Sameer Merchant
p. 11
“So, we plan to deploy CAPEX based on the operational capabilities. So, we see the revenues growing and based on that, we will keep balancing out CAPEX.”
Sameer Merchant, page 11 of the filed PDF · View the filing
Dental lab business growth — next two to three years
stated as an aspiration by Sameer Merchant
p. 9
“we are confident on the next two to three years that this will continue growing.”
Sameer Merchant, page 9 of the filed PDF · View the filing
Vedia raw metal business expansion — next 2 to 3 years
stated as an aspiration by Sameer Merchant
p. 8
“we are confident that this business, we should be able to expand it in multiple countries. And we should see some good results over the next 2 to 3 years.”
Sameer Merchant, page 8 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said they preserved margins over growth and saw a genuine recovery in Q4, while continuing to balance pricing against growth.
Answered by Sameer Merchant
Asked by Ajay: What drove the Bizdent Q4 recovery - pricing normalization or genuine volume growth?
p. 7
“we wanted on our side as management to preserve the margins. And I think we have done that.”
Sameer Merchant, page 7 of the filed PDF · View the filing
Management said both domestic and international lab businesses are expected to keep growing over the next two to three years, though a specific number could not be given.
Answered by Sameer Merchant
Asked by Kaushal Shah: What is the outlook for the dental lab business run rate over the next two years?
p. 9
“we are confident on the next two to three years that this will continue growing. Now to give you a pinpoint number today as on today may not be possible.”
Sameer Merchant, page 9 of the filed PDF · View the filing
Management said it could not guide specifically but wants to do better over the next two to three years, and does not see a challenge to growing at a similar trajectory as before.
Answered by Sameer Merchant
Asked by Deepak Poddar: Can current margin levels be maintained into FY27?
p. 11
“I wish I could guide you at this point in time. But you know how the situation is. But on our side, internally, if you ask us, we definitely want to do better than what we have done over the next two to three years.”
Sameer Merchant, page 11 of the filed PDF · View the filing
Management said the US contributes 20% of revenue, tariffs have improved from a prior high level to about 10%, and this is not seen as a deal breaker.
Answered by Sameer Merchant
Asked by Nitish Gupta: What is the US export percentage and outlook after tariff normalization?
p. 14
“At 10%, it's not a deal breaker. So, 10% does not create a situation where business can't be done.”
Sameer Merchant, page 14 of the filed PDF · View the filing
Management said there has been no change with Heartland, the US business situation has improved, and they will continue adding DSOs without necessarily naming them.
Answered by Sameer Merchant
Asked by Ajay: Is there any renewal risk with Heartland Dental given tariffs, and are more DSOs being added?
p. 15
“there has been no change. In fact, like I said, the situation has become better than what it was 50% to 10%. So, we don't see any challenge for the U.S. business.”
Sameer Merchant, page 15 of the filed PDF · View the filing
Management said registration timelines from regulatory bodies are unpredictable and they will announce achievement of registration rather than give a timeline.
Answered by Sameer Merchant
Asked by Ajay: What is the timeline for international registrations for Kids-e-Dental (pediatric dental)?
p. 16
“right now, like you said, we are in active phase of registration. We have cleared a few steps of registration.”
Sameer Merchant, page 16 of the filed PDF · View the filing
Risks flagged
US tariff volatility weighing on EBITDA margin
p. 4
“The improvement in the margin is despite a half-quarter impact of US tariff, weighing on our EBITDA margin by around 74 bps.”
Rajesh Khakhar, page 4 of the filed PDF · View the filing
Intensifying competition in the domestic aligner segment
p. 3
“Our annual performance is especially noteworthy as it was delivered amid a challenging global environment marked by US tariff volatility, intensifying competition in the domestic aligner segment, labor code transitions and several other external headwinds during FY '26.”
Rajesh Khakhar, page 3 of the filed PDF · View the filing
Higher freight costs delaying Vedia shipments
p. 9
“there were some shipments, which we could not send because of the higher freight costs for the current situation because the freight cost was almost double or some in scenarios almost 3x.”
Sameer Merchant, page 9 of the filed PDF · View the filing
Cautious, gradual scale-up in US business due to uncertain environment
p. 5
“due to uncertain environment, the scale-up in the US business happened gradually in a cautious manner.”
Sameer Merchant, page 5 of the filed PDF · View the filing
Unpredictable regulatory approval timelines for international registrations
p. 16
“this is all regulatory bodies. So, it's very, very hard to predict.”
Sameer Merchant, page 16 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.